COWEN, NEIL M.,KASHKIN, KENNETH B.,COWEN NEIL M,KASHKIN KENNETH B
申请号：
ES11184285
公开号：
ES2539969T3
申请日:
2005.08.25
申请国别(地区):
ES
年份:
2015
代理人:
摘要：
A pharmaceutical controlled release formulation comprising a KATP channel activator of ** Formula ** wherein in Formulas II and III: R 1 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl and cycloalkyl replaced； R2a is selected from the group consisting of hydrogen and lower alkyl； R2b is selected from the group consisting of hydrogen and lower alkyl； X is a chain of 1, 2 or 3 atoms, in which each atom is independently selected from carbon, sulfur and nitrogen, and each atom is optionally substituted with halogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, cycloalkyl, substituted cycloalkyl, substituted lower alkoxy, amino and substituted amino； and ring B is saturated, monounsaturated, polyunsaturated or aromatic, and wherein in Formulas IV and V: R1 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl and substituted cycloalkyl； R2a is selected from the group consisting of hydrogen, lower alkyl and substituted lower alkyl； R2b is selected from the group consisting of hydrogen, lower alkyl and substituted lower alkyl； R3 is selected from the group consisting of hydrogen, halogen, lower alkyl, substituted lower alkyl, amino and substituted amino； and R4 is selected from the group consisting of hydrogen, halogen, lower alkyl, substituted lower alkyl, amino and substituted amino； for use in a method of treatment of obesity or elevated triglycerides in a patient suffering from type I, type II, type III or type IV hyperlipoproteinemia, which comprises administration to said subject once every 24 hours of a therapeutically effective amount of said controlled release formulation, wherein the amount of said KATP channel activator administered to said patient is between 50 and 275 mg / day.Una formulación farmacéutica de liberación controlada que comprende un activador del canal de KATP de**Fórmula** en donde en las Fórmulas II y III: R1 se selecciona entre el
